Cleary Gottlieb is representing Goldman Sachs, as financial advisor to Valeant Pharmaceuticals International, Inc., in the sale of its iNova Pharmaceuticals business to a company jointly owned by funds advised and managed by Pacific Equity Partners and The Carlyle Group for $930 million in cash.
The deal signed on June 8, 2017, and is expected to close in the second half of 2017.
Valeant Pharmaceuticals International, Inc. is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics.